A psoriasis drug is now approved to treat psoriatic arthrits in adults. READ MORE

News

A psoriasis drug is now approved to treat psoriatic arthrits in adults.

READ MORE

The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.

READ MORE

Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.

READ MORE

An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.

READ MORE

Research in Review

A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.

READ MORE

Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.

READ MORE

Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.

READ MORE

A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.

READ MORE

Resources

The first guidelines on the use of disease-modifying therapies in multiple sclerosis have been issued by the European Committee for Research and Treatment of Multiple Sclerosis and the European Academy of Neurology.

READ MORE